O desenvolvimento da autonomia no discurso de adolescentes de origem italiana

95

Effects of Indigofera suffruticosa Mill (Fabaceae) on the developmental reproductive biology of Aedes aegypti / Efeitos da Indigofera Suffruticosa Mill (Fabaceae) na biologia reprodutiva do desenvolvimento de Aedes aegypti

Moinho Indigofera suffruticosa (Fabaceae) ocorre em abundância no nordeste do Brasil. Suas várias atividades biológicas incluem uma eficácia do extrato aquoso das folhas de I. sufruticosa na inibição da eclosão dos ovos e da ecdise larval, e efeitos dissuasivos na oviposição do mosquito Aedes aegypti . Este estudo investiga uma biologia reprodutiva de A. aegypti exposto à solução aquosa de folhas de I. suffruticosa (AELIs). O desenvolvimento dos órgãos reprodutivos foi investigado utilizando larvas de último instar (L4) de A. aegypti na presença de AELIs.Um tratamento com água destilada para controle. Os experimentos foram realizados após medidas de testículos e glândulas acessórias e da análise do comportamento reprodutivo durante o acasalamento de mosquitos expostos aos AELIs por 24 h. Havia três tratamentos: (1) controle: machos sem exposição aos AELIs; (2) AELIs24h: machos após a exposição de AELIs copulada na ausência de AELIs; (3) AELIs24h + G: machos após a exposição de AELIs copulada na presença de AELIs. Os efeitos dos AELIs na fase larval não interferem no desenvolvimento do tamanho dos órgãos reprodutivos. Além disso, a exposição ao tratamento AELIs24h interfere no comportamento reprodutivo, devido ao número de cópulas.Por outro lado, AELIs24h + G apresentou um aumento significativo no número de cópulas, o que resultou em uma diminuição drástica no número de ovos aumentadas. Este estudo completo que uma espécie I. suffruticosa (AELIs) pode ser usada como uma nova alternativa metodológica para o controle de A. aegypti por ser um produto natural

Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease

Pompe disease (PD) is a potentially lethal illness involving irreversible muscle damage resulting from glycogen storage in muscle fiber and activation of autophagic pathways. A promising therapeutic perspective for PD is enzyme replacement therapy (ERT) with the human recombinant enzyme acid alpha-glucosidase (Myozyme (R)). The need to organize a diagnostic flowchart, systematize clinical follow-up, and establish new therapeutic recommendations has become vital, as ERT ensures greater patient longevity. A task force of experienced clinicians outlined a protocol for diagnosis, monitoring, treatment, genetic counseling, and rehabilitation for PD patients. The study was conducted under the coordination of REBREPOM, the Brazilian Network for Studies of PD. The meeting of these experts took place in October 2013, at L'Hotel Port Bay in Sao Paulo, Brazil. In August 2014, the text was reassessed and updated. Given the rarity of PD and limited high-impact publications, experts submitted their views.Inst Fernandes Figueira FIOCRUZ, Dept Med Genet, Rio De Janeiro, RJ, BrazilUniv Fed Fluminense, Dept Neurol & NeuroUPC, BR-22031171 Rio De Janeiro, RJ, BrazilUniv Fed Sao Paulo, Dept Neurol, Sao Paulo, SP, BrazilUniv Fed Rio Grande do Norte, Dept Neurol, Caiaco, RN, BrazilClin Marrone, Porto Alegre, RS, BrazilUniv Cuiaba, Dept Neurol, Cuiaba, MT, BrazilUniv Sao Paulo, Dept Neurociencias, BR-14049 Ribeirao Preto, SP, BrazilHosp Base Dist Fed, Serv Neurol, Brasilia, DF, BrazilUniv Fed Parana, Serv Doencas Neuromusculares, BR-80060000 Curitiba, Parana, BrazilUniv Fed Sao Paulo, Dept Neurol, Sao Paulo, SP, BrazilWeb of Scienc

First use of antineoplastic agents in women with breast cancer in the state of Rio de Janeiro, Brazil

Context: Breast cancer is the most common cancer, except for non-melanoma skin cancer, among women in Brazil and worldwide. Breast cancer treatment involves surgery, radiotherapy and chemotherapy, which is used in 70% of patients. This study analyzes the utilization of antineoplastic agents among women undergoing their first round of chemotherapy in Brazil’s public health system (SUS) in the state of Rio de Janeiro.Methods: Data from the SUS Outpatient Information System’s authorizations for high-complexity outpatient procedures (APACs) billed between January 2013 and December 2019 were extracted, and three datasets were created: all type 1 and type 2 APACs (including all chemotherapy procedures performed); all type 1 APACs; and first type 1 APACs (containing data only for the first round of breast cancer chemotherapy). Names of antineoplastic agents were standardized to enable the subsequent classification of therapy regimens, mitigating limitations related to data quality. Absolute and relative frequencies were used to describe sociodemographic, clinical and treatment characteristics, therapy regimen and supportive drugs.Results: We analyzed 23,232 records of women undergoing their first round of chemotherapy. There was a progressive increase in the number of procedures over time. Women were predominantly white, lived in the capital and close to the treatment center. Most had stage 3 cancer at diagnosis (50.51%) and a significant proportion had regional lymph node invasion (37.9%). The most commonly used chemotherapy regimens were TAC (docetaxel, doxorubicine, cyclophosphamide) (21.05%) and and cyclophosphamide (17.71%), followed by tamoxifen (15.65%) and anastrozole (12.94%). Supportive drugs were prescribed to 386 women and zoledronic acid was predominant (59.58%).Conclusion: The findings point to important bottlenecks and possible inequities in access to treatment and medicine utilization for breast cancer patients in Brazil. Efforts to improve breast cancer treatment and prevention should not only focus on interventions at the individual level but address the disease as a public health problem. The study focused on women undergoing their first round of treatment, providing valuable insight into patient and treatment characteristics to inform policy decisions

Phytochemical Approach and Evaluation of the Osmotic Fragility and Cytotoxic Activity of Piptadenia stipulacea (Benth) Ducke / Abordagem Fitoquímica e Avaliação da Fragilidade Osmótica e Atividade Citotóxica de Piptadenia stipulacea (Benth) Ducke

Piptadenia stipulacea (Benth.) Ducke, Fabaceae, is a medicinal plant that can be found in the Caatinga is the only exclusively Brazilian biome. Various biological activities, such as antimicrobial, anti-inflammatory, antifungal and antioxidant activities are reported for this plant. This work investigated the chemical compounds present in the ethanolic extract of the leaves of P. stipulacea (EELPs), being used in the test of osmotic fragility in the blood of sheep and cytotoxic and genotoxic effect in the Allium cepa test with onion roots. Phytochemical analysis were performed by thin-layer chromatography.  Results revealed the presence of tannin, alkaloids, saponins, cumarins, flavonoids and terpenes. The erythrocyte osmotic fragility test showed low hemolysis levels, in the qualitative evaluation of the supernatant and in the result of the hemolytic percentage. Cytological examination with Allium cepa with different concentration EELPs (50 µg.mL-1, 500 µg.mL-1 e 1000 µg.mL-1) no chromosomal abnormality were identified in the cell division process  (Interphase, prophase, metaphase, anaphase, telophase) in relation to the  control group. However, the EELPs at the concentration of 50 µg.mL-1 presented a root development when compared to 500 µg.mL-1 and 1000 µg.mL-1. This demonstrates a pharmacological importance of this plant and low hemolysis index, cell membrane integrity and low toxicity absence of chromosomal abnormality. The results suggest that P. stipulacea may present antigenotoxic

Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy

Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is a rare fatal autorecessive disease. Halter et al. report outcomes from all known haematopoietic stem cell transplantations worldwide from sibling or unrelated donors for MNGIE between 2005 and 2011. In some of the recipients, correction of the underlying metabolic defect results in gradual clinical improvemen

The Ninth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the SDSS-III Baryon Oscillation Spectroscopic Survey

The Sloan Digital Sky Survey III (SDSS-III) presents the first spectroscopic data from the Baryon Oscillation Spectroscopic Survey (BOSS). This ninth data release (DR9) of the SDSS project includes 535,995 new galaxy spectra (median z=0.52), 102,100 new quasar spectra (median z=2.32), and 90,897 new stellar spectra, along with the data presented in previous data releases. These spectra were obtained with the new BOSS spectrograph and were taken between 2009 December and 2011 July. In addition, the stellar parameters pipeline, which determines radial velocities, surface temperatures, surface gravities, and metallicities of stars, has been updated and refined with improvements in temperature estimates for stars with T_eff<5000 K and in metallicity estimates for stars with [Fe/H]>-0.5. DR9 includes new stellar parameters for all stars presented in DR8, including stars from SDSS-I and II, as well as those observed as part of the SDSS-III Sloan Extension for Galactic Understanding and Exploration-2 (SEGUE-2). The astrometry error introduced in the DR8 imaging catalogs has been corrected in the DR9 data products. The next data release for SDSS-III will be in Summer 2013, which will present the first data from the Apache Point Observatory Galactic Evolution Experiment (APOGEE) along with another year of data from BOSS, followed by the final SDSS-III data release in December 2014.Comment: 9 figures; 2 tables. Submitted to ApJS. DR9 is available at http://www.sdss3.org/dr